Clostridium difficile infection in patients with inflammatory bowel disease: a case control study

References

• Lewis SS, Anderson DJ. Treatment of Clostridium difficile infection: recent trial results. Clin Investig (Lond). 2013;3:875–886.
   PubMedGoogle Scholar
• Molodecky NA. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12(Suppl 1):S3–S9.
   PubMed Web of Science ®Google Scholar
• Law CCY, Tariq R, Khanna S, et al. Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short- and long-term risks of colectomy in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(8):1011–1020.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(6):1443–1450.
   PubMed Web of Science ®Google Scholar
• Razik R, Rumman A, Bahreini Z, et al. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM study. Am J Gastroenterol. 2016;111(8):1141–1146.
   Web of Science ®Google Scholar
• Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103(9):2308–2313.
   PubMed Web of Science ®Google Scholar
• Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–1010.
   PubMed Web of Science ®Google Scholar
• Bloomfield LE, Riley TV. Epidemiology and risk factors for community-associated Clostridium difficile infection: a narrative review. Infect Dis Ther. 2016;5(3):231–251.
   Web of Science ®Google Scholar
• Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345–351.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57(2):205–210.
   PubMed Web of Science ®Google Scholar
• Micic D, Yarur A, Gonsalves A, et al. Risk factors for Clostridium difficile isolation in inflammatory bowel disease: a prospective study. Dig Dis Sci. 2018;63(4):1016–1024.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30(3):253–264.
   PubMed Web of Science ®Google Scholar
• Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am J Gastroenterol. 2010;105(9):2040–2049.
   PubMed Web of Science ®Google Scholar
• Berg AM, Kelly CP, Farraye FA. Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis. 2013;19(1):194–204.
   PubMed Web of Science ®Google Scholar
• Antikainen J, Pasanen T, Mero S, et al. Detection of virulence genes of Clostridium difficile by multiplex PCR. APMIS. 2009;117(8):607–613.
   PubMed Web of Science ®Google Scholar
• Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009;104(5):1162–1169.
   PubMed Web of Science ®Google Scholar
• Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):339–344.
   PubMed Web of Science ®Google Scholar
• Khanna S, Shin A, Kelly CP. Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the clinical practice updates committee of the AGA institute. Clin Gastroenterol Hepatol. 2017;15(2):166–174.
   PubMed Web of Science ®Google Scholar
• D’Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol. 2017;23(27):4986–5003.
   PubMed Web of Science ®Google Scholar
• Liu F. Azathioprine, mercaptopurine, and 5-aminosalicylic acid affect the growth of IBD-associated campylobacter species and other enteric microbes. Front Microbiol. 2017;8:527.
   PubMed Web of Science ®Google Scholar
• Andrews CN, Griffiths TA, Kaufman J, et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34(3):374–383.
   PubMed Web of Science ®Google Scholar
• Bossuyt P, Verhaegen J, Van Assche G, et al. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis. 2009;3(1):4–7.
   PubMed Web of Science ®Google Scholar
• Fu N, Wong T. Clostridium difficile infection in patients with inflammatory bowel disease. Curr Infect Dis Rep. 2016;18(6):19.
   PubMed Web of Science ®Google Scholar
• Pepin J, Saheb N, Coulombe M-A, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254–1260.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7(2):107–112.
   PubMed Web of Science ®Google Scholar